Navigation Links
Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
Date:6/2/2008

Company Developing Non-Nucleoside Polymerase Inhibitor for Treatment of

Hepatitis C

SAN DIEGO, June 2 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today the initiation of dosing in a Phase I clinical trial of ANA598, an investigational oral non-nucleoside polymerase inhibitor for the treatment of chronic hepatitis C virus (HCV) infection. The objectives of this trial are to assess safety, tolerability, and pharmacokinetics following ascending single oral doses of ANA598 in healthy volunteers. Approximately 40 healthy subjects will participate in the study, which is being conducted in the United States. Following successful completion of the healthy volunteer study, Anadys plans to begin a Phase Ib study of ANA598 in HCV-infected patients in the third quarter of 2008.

"Based on its very favorable preclinical profile, including potency, pharmacokinetics, and tolerability, we believe ANA598 has the potential to become an important component of future combination therapy for patients with HCV infection," said James Freddo, M.D., Anadys' Chief Medical Officer. "We are excited about initiating this clinical program and look forward to future trials of ANA598 in HCV patients, first as a single agent and then in subsequent combination studies. We expect the full benefit of direct antivirals to be demonstrated when studied as components of novel combination regimens incorporating multiple anti-HCV agents."

Steve Worland, Ph.D., Anadys' President and CEO commented, "This is a significant milestone for Anadys. ANA598 is the second internally discovered compound that we've moved into clinical studies this year. With the commencement of dosing in a Phase I clinical
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)...   Plexus Information Systems, Inc. (Plexus ... Systems (AIMS), announced a partnership with NextGen ... subsidiary of Quality Systems, Inc. and a leading ... Logo - http://photos.prnewswire.com/prnh/20140930/149406 ... This partnership extends the NextGen Healthcare product portfolio ...
(Date:10/1/2014)... NeuroCall, Inc., ("NeuroCall") announced today that it ... Teleneurology services. Dr. Ricardo Garcia-Rivera , Founder and ... proud that our quality of service has been recognized ... lifesaving support and continuity of care to patients of ... the United States ." NeuroCall ...
(Date:10/1/2014)... Oct. 1, 2014 Quantum Materials Corp ... production of photoactive quantum dots for use in ... offering numerous advantages for solar power generation, the ... of quantum dots with which to develop thin ... from commercial utilization and acceptance. The company is ...
Breaking Medicine Technology:Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 2Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 3NeuroCall Awarded Joint Commission Accreditation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 3
... Every Four-Week Subcutaneous Golimumab Also Experienced ... and Disease Activity, PARIS, June 11 Findings ... every four-week subcutaneous injections of,golimumab (CNTO 148) 50 mg ... in the signs and symptoms of,rheumatoid arthritis (RA) as ...
... maintenance ... compared to placebo, BRIDGEWATER, N.J., June 10 Sanofi-aventis,announced ... (zolpidem,tartrate extended-release) CIV tablets 12.5 mg provided significant,improvement in sleep ... patients with co-morbid insomnia and major depressive disorder,(MDD) who were ...
Cached Medicine Technology:Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis 2Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis 3Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis 4Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis 5Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis 6Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis 7Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis 8Ambien CR(R) (zolpidem tartrate extended-release) CIV Tablets Improved Insomnia and Daily Functioning in Patients with Co-Morbid Major Depressive Disorder 2Ambien CR(R) (zolpidem tartrate extended-release) CIV Tablets Improved Insomnia and Daily Functioning in Patients with Co-Morbid Major Depressive Disorder 3Ambien CR(R) (zolpidem tartrate extended-release) CIV Tablets Improved Insomnia and Daily Functioning in Patients with Co-Morbid Major Depressive Disorder 4Ambien CR(R) (zolpidem tartrate extended-release) CIV Tablets Improved Insomnia and Daily Functioning in Patients with Co-Morbid Major Depressive Disorder 5
(Date:10/1/2014)... (PRWEB) October 01, 2014 Familylifeinsurancequotes.org ... find life insurance for senior citizens. , Senior ... Agencies will now sell coverage to seniors who are ... can be purchased without taking a medical examination. , ... purchased online and senior clients can qualify. Having life ...
(Date:10/1/2014)... Lifeinsurance-policy.com has released a new blog post ... for smokers. , Smoking will always have a negative ... the best method to find affordable coverage. Insurance brokerage ... coverage. , Whole life insurance premiums will be ... the coverage is permanent, the initial rates are ...
(Date:10/1/2014)... 01, 2014 Farmington Company today ... redefined mission and visual identity helping brokers, consultants ... with them to create greater benefit communication synergies. ... focuses on empowering customers to better leverage Farmington ... crown jewel of the rebrand is the refreshed ...
(Date:10/1/2014)... 2014 Between 23 million and 50 ... according to figures from the National Institutes of Health ... and many of them have something else in common: ... celiac disease. Gluten Free Therapeutics, makers of CeliVites ... celiac disease by publishing a series of blog posts ...
(Date:10/1/2014)... Toronto, Canada (PRWEB) October 01, 2014 ... hair removal and skin rejuvenating destination of choice, is ... run from October through to December. , “We’re doing ... access as possible to our top skin clinic in ... Clinic. “We do so much at Anti Aging Clinic, ...
Breaking Medicine News(10 mins):Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3Health News:Anti Aging Clinic, the GTA’s Premier Provider of Anti Aging Treatments, Announces Deal on Units of Botox 2
... LANCASTER, Pa., June 12 Herley Industries,Inc. (Nasdaq: ... third quarter,ended May 4, 2008. Herley reported net sales ... or 13% from the third quarter of the prior,fiscal ... of $0.27 per share including,the impact of a litigation ...
... allow physicians to more accurately diagnose and treat ... University to Syntermed, an Atlanta-based nuclear medicine imaging ... phase analysis (MHPA), a technology developed by Emory ... PhD. , MHPA is designed to quickly and ...
... and molecular machinery is pointing toward new drugs and ... emerging era of personalized medicine, in which doctors aim ... for the right patient, also brings concerns about genetic ... , The American Association for the Advancement of ...
... TULSA, Okla., June 12 Do you know ... those individuals and,organizations working to improve Oklahoma,s health. ... of those who are making a,significant difference in ... the deadline of Friday, Aug. 1., Nominations ...
... Clear Need for Continued Industry Commitment to Health IT Privacy and ... ... June 12 As consumer options for online,health management expand, there ... complex technologies contribute to,better health and added convenience. Wide-spread adoption requires ...
... June 12 Best Practices, LLC,conducted this study ... used by companies across various industries to measure,the ... pharmaceutical industry, number of sales calls is most ... manufacturing,companies employ year over year account revenue growth ...
Cached Medicine News:Health News:Herley Reports Third Quarter Results 2Health News:Herley Reports Third Quarter Results 3Health News:Herley Reports Third Quarter Results 4Health News:Herley Reports Third Quarter Results 5Health News:Herley Reports Third Quarter Results 6Health News:Herley Reports Third Quarter Results 7Health News:Herley Reports Third Quarter Results 8Health News:Herley Reports Third Quarter Results 9Health News:Herley Reports Third Quarter Results 10Health News:Herley Reports Third Quarter Results 11Health News:Herley Reports Third Quarter Results 12Health News:Herley Reports Third Quarter Results 13Health News:Syntermed licenses Emory imaging technology for improved evaluation of heart failure patients 2Health News:AAAS hosts June 20 conference on personalized medicine 2Health News:Nominations Accepted for 2008 'Champions of Health' Awards 2Health News:More Americans Aware of Digital Health Options; Use of Health IT Increases 2Health News:More Americans Aware of Digital Health Options; Use of Health IT Increases 3Health News:More Americans Aware of Digital Health Options; Use of Health IT Increases 4Health News:Benchmarking Study Report on Sales Performance Management 2
... Agilis Steerable Introducer helps physicians ... right or left atrium. With ... tip, and radiopaque tip marker, ... the agility and stability needed ...
... 70 RF Generator introduces maximum ... every day, in every ablation ... and the CARTO EP Navigation ... Catheter provide clinicians with a ...
The Microny pacemakers are among the smallest devices in the world. The Microny II SR+ pacemaker is the world's smallest, single-chamber rate-responsive pulse generator. The Microny pacemakers featur...
... family of pacemakers features several ... truly automatic devices in today's ... unparalleled combination of automated features ... builds on the popular and ...
Medicine Products: